BACKGROUND: Adjuvant hormone therapy (AHT) following radiotherapy or surgery is a treatment option frequently offered to men with localised or locally advanced prostate cancer. We performed a systematic review of published randomised trials to assess the effectiveness of AHT. METHODS: We searched MEDLINE, EMBASE, the Cochrane library, SCI, LILACS and SIGLE for randomised trials comparing AHT plus primary therapy (radiotherapy or prostatectomy) with primary therapy alone. Data on study design, participants interventions and outcomes were extracted from relevant studies and where possible pooled for meta-analysis. FINDINGS: AHT following radiotherapy improved overall survival (at 5 years OR fixed effect model 1.29, 95% CI 1.07-1.56, p=0.007), disease-specific survival (OR 2.10, 95% CI 1.53-2.88, p<0.00001) and disease-free survival (OR 1.91, 95% CI 1.16-2.23, p<0.00001). A random effect model favoured adjuvant hormone therapy but did not reach significance. After prostatectomy, there was no significant overall survival advantage with AHT, although one study reported a significant improvement in disease-specific survival (HR 4.09, p=0.0004). Disease-free survival was also better with AHT (OR 3.73, 95% CI 2.30-6.03, p<0.00001). AHT-induced toxicities included gynaecomastia, impotence, gastrointestinal and haematological. CONCLUSIONS: There are significant clinical benefits associated with the use of AHT for early prostate cancer. Patients should make an informed decision to accept AHT based on its effectiveness and side-effects.
BACKGROUND: Adjuvant hormone therapy (AHT) following radiotherapy or surgery is a treatment option frequently offered to men with localised or locally advanced prostate cancer. We performed a systematic review of published randomised trials to assess the effectiveness of AHT. METHODS: We searched MEDLINE, EMBASE, the Cochrane library, SCI, LILACS and SIGLE for randomised trials comparing AHT plus primary therapy (radiotherapy or prostatectomy) with primary therapy alone. Data on study design, participants interventions and outcomes were extracted from relevant studies and where possible pooled for meta-analysis. FINDINGS: AHT following radiotherapy improved overall survival (at 5 years OR fixed effect model 1.29, 95% CI 1.07-1.56, p=0.007), disease-specific survival (OR 2.10, 95% CI 1.53-2.88, p<0.00001) and disease-free survival (OR 1.91, 95% CI 1.16-2.23, p<0.00001). A random effect model favoured adjuvant hormone therapy but did not reach significance. After prostatectomy, there was no significant overall survival advantage with AHT, although one study reported a significant improvement in disease-specific survival (HR 4.09, p=0.0004). Disease-free survival was also better with AHT (OR 3.73, 95% CI 2.30-6.03, p<0.00001). AHT-induced toxicities included gynaecomastia, impotence, gastrointestinal and haematological. CONCLUSIONS: There are significant clinical benefits associated with the use of AHT for early prostate cancer. Patients should make an informed decision to accept AHT based on its effectiveness and side-effects.
Authors: Alejandro D Soriano-Hernández; Hector R Galvan-Salazar; Daniel A Montes-Galindo; Alejandrina Rodriguez-Hernandez; Rafael Martinez-Martinez; Jose Guzman-Esquivel; Laura L Valdez-Velazquez; Luz M Baltazar-Rodriguez; Francisco Espinoza-Gómez; Augusto Rojas-Martinez; Rocio Ortiz-Lopez; Rafael Gonzalez-Alvarez; Ivan Delgado-Enciso Journal: Int Urol Nephrol Date: 2011-06-10 Impact factor: 2.370
Authors: Kim Edmunds; Haitham Tuffaha; Daniel A Galvão; Paul Scuffham; Robert U Newton Journal: Support Care Cancer Date: 2020-01-07 Impact factor: 3.603
Authors: Young Hwii Ko; Seok Ho Kang; Young Je Park; Hong Seok Park; Du Geon Moon; Jeong Gu Lee; Duck Ki Yoon; Je Jong Kim; Jun Cheon Journal: Asian J Androl Date: 2010-08-16 Impact factor: 3.285
Authors: A Creak; E Hall; A Horwich; R Eeles; V Khoo; R Huddart; C Parker; C Griffin; M Bidmead; J Warrington; D Dearnaley Journal: Br J Cancer Date: 2013-07-23 Impact factor: 7.640